VRTX
BuyPremium GrowerFLAGVertex Pharmaceuticals Incorporated · Healthcare · United States · $137.3B · Avg Vol: $556M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Vertex Pharmaceuticals has exceptional quality Q78 and momentum M65 with a buyback, but value at V28 is well below the calibrated floor, and insiders sold, so stage one fails.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT VERTEX PHARMACEUTICALS INCORPORATED
Read
Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, primarily cystic fibrosis (CF). It holds a dominant market position in CF treatments with proprietary, highly effective therapies that address the disease's underlying causes. Vertex is a leader in precision medicines, utilizing deep scientific expertise to target genetic mutations and expanding into other therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.9B | 9.9B | 11.0B | 12.0B | 10.4% | 12.6B | 13.2B | 14.5B | 10.0% |
| EPS | 12.97 | 14.05 | -2.08 | 15.46 | 6.0% | 17.19 | 13.46 | 16.92 | 4.6% |
| Shares | 257.0M | 257.7M | 256.9M | 254.0M | -1.2% | 253.5M | — | — | — |
| Debt | 899.7M | 808.4M | 1.7B | 2.0B | 31.2% | 2.0B | — | — | — |
| Equity | 13.9B | 17.6B | 16.4B | 18.7B | 10.3% | — | — | — | — |
| Op CF | 4.1B | 3.5B | -492.6M | 3.6B | -4.2% | 4.3B | — | — | — |
| Inv CF | -321.1M | -3.1B | -3.8B | -945.4M | — | — | — | — | — |
| Fin CF | -67.7M | -562.2M | -1.5B | -2.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VRTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated(you) | $137.3B | 68 | Buy |
| ARGX.BR | argenx SE | $64.5B | 74 | Buy |
| 688235.SS | BeOne Medicines AG | $59.5B | 61 | Hold |
| REGN | Regeneron Pharmaceuticals, Inc. | $81.8B | 85 | Strong Buy |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| 207940.KS | Samsung Biologics Co.,Ltd. | $50.2B | 52 | Hold |
| 1801.HK | Innovent Biologics, Inc. | $23.9B | 71 | Buy |
| RPRX | Royalty Pharma plc | $35.2B | 56 | Hold |
| GMAB | Genmab A/S | $20.4B | 65 | Buy |
| CSL.AX | CSL Limited | $38.0B | 85 | Strong Buy |
Peer medians: ROE 2.7% · P/E 23.5x · Gross margin 52.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.